Date: 2015-01-12
Type of information: Collaboration agreement
Compound: DNA structural variants linked to prostate and breast cancers
Company: Ariana Pharma (France) Nabsys (USA - RI)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On January 12, 2015, Nabsys, a life sciences company pioneering semiconductor-based tools for human genomic analysis in oncology, and Ariana Pharmaceuticals SA, a developer of innovative clinical data analysis and diagnostic solutions for the healthcare sector, announced a collaboration that aims to identify sets of DNA structural variants linked to prostate and breast cancers and to the clinical outcome of patients with these diseases through the analysis of public genome databases. Through the partnership, the two companies will develop a single database each for the analysis of Prostate Adenocarcinomas and for the analysis of Breast Cancer. The generation of two signatures comprised of previously-identified DNA structure variations will improve individual predictive capabilities and will ultimately be employed in personalize treatment plans.
Financial terms:
Latest news:
